Morgan Stanley’s Biohaven BHVN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$12.5M Sell
841,351
-185,581
-18% -$2M ﹤0.01% 3518
2026
Q1
$8.69M Buy
1,026,932
+51,736
+5% +$566K ﹤0.01% 3680
2025
Q4
$11M Buy
975,196
+429,381
+79% +$5.32M ﹤0.01% 3527
2025
Q3
$8.19M Sell
545,815
-191,861
-26% -$2.79M ﹤0.01% 3716
2025
Q2
$10.4M Sell
737,676
-221,237
-23% -$3.94M ﹤0.01% 3404
2025
Q1
$23.1M Buy
958,913
+176,256
+23% +$6.22M ﹤0.01% 2549
2024
Q4
$29.2M Buy
782,657
+218,780
+39% +$10.2M ﹤0.01% 2372
2024
Q3
$28.2M Sell
563,877
-154,925
-22% -$6.03M ﹤0.01% 2445
2024
Q2
$24.9M Buy
718,802
+70,410
+11% +$2.78M ﹤0.01% 2427
2024
Q1
$35.5M Buy
648,392
+57,410
+10% +$2.84M ﹤0.01% 2092
2023
Q4
$25.3M Buy
590,982
+239,962
+68% +$7.46M ﹤0.01% 2439
2023
Q3
$9.13M Buy
351,020
+26,273
+8% +$546K ﹤0.01% 3208
2023
Q2
$7.77M Buy
324,747
+15,649
+5% +$269K ﹤0.01% 3417
2023
Q1
$4.22M Buy
309,098
+24,730
+9% +$394K ﹤0.01% 3916
2022
Q4
$3.95M Buy
284,368
+267,026
+1,540% +$3.77M ﹤0.01% 3957
2022
Q3
$107K Buy
+17,342
New +$126K ﹤0.01% 6044

Other funds holding BHVN

Morgan Stanley's BHVN Position: Q2 2026 in Review

Morgan Stanley reduced its Biohaven (BHVN) stake by 18% in Q2 2026, selling an estimated $2M and leaving 841,351 shares worth $12.5M. The position accounts for ﹤0.01% of the portfolio, ranked #3518.

Morgan Stanley first reported a position in BHVN in Q3 2022 and has held it in 16 quarters since. The position peaked at $35.5M in Q1 2024. 292 funds tracked by Wall St. Rank hold BHVN as of Q2 2026.

  • Morgan Stanley held 841,351 shares of Biohaven worth $12.5M as of Q2 2026.
  • Morgan Stanley sold 185,581 Biohaven shares in Q2 2026, an estimated $2M.
  • Biohaven made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #3518 holding.
  • Morgan Stanley first reported a position in Biohaven in Q3 2022 and has held it in 16 quarters since.
  • Morgan Stanley's Biohaven position peaked at $35.5M in Q1 2024.
  • 292 funds tracked by Wall St. Rank held Biohaven as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.